09/2025 |
Nat Neurosci Potentiation of mitochondrial function by mitoDREADD-G(s) reverses pharmacological and neurodegenerative cognitive impairment in mice.Pagano Zottola AC, Martin-Jimenez R, Lavanco G, Hamel-Cote G, Ramon-Duaso C, Rodrigues RS, Mariani Y, Khan M, Drago F, Jean S, Rio IB, Jimenez-Blasco D, Egana-Huguet J, Eraso-Pichot A, Beriain S, Cannich A, Vidal-Palencia L, Infantino R, Julio-Kalajzic F, Gisquet D, Goncalves A, Al-Younis I, Baussan Y, Duvezin-Caubet S, Devin A, Soria-Gomez E, Puente N, Bolanos JP, Grandes P, Pouvreau S, Busquets-Garcia A, Marsicano G, Bellocchio L, Hebert-Chatelain E
Abstract:
Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (G(s)) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-G(s)) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-G(s) abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-G(s) enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment.